Cargando…

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Docetaxel remains a cornerstone of therapy for the patient with metastatic castration-resistant prostate cancer (CRPC). However, the landscape of CRPC therapy is changing rapidly – recently, data from the phase III TROPIC study revealed a survival advantage with the novel taxane cabazitaxel/predniso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pal, Sumanta Kumar, Twardowski, Przemyslaw, Sartor, Oliver
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998247/ https://www.ncbi.nlm.nih.gov/pubmed/21152241 http://dx.doi.org/10.2147/CIA.S14570

Ejemplares similares

Management of localized prostate cancer: the pendulum swings (back to the middle)
por: Vuong, Winston, et al.
Publicado: (2014)

Current clinical challenges in prostate cancer
por: Silberstein, Jonathan L., et al.
Publicado: (2013)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Feasibility of cabazitaxel in octogenarian prostate cancer patients
por: Tralongo, Paolo, et al.
Publicado: (2023)

Preclinical profile of cabazitaxel
por: Vrignaud, Patricia, et al.
Publicado: (2014)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2016)

Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer
por: Nlandu, Yannick, et al.
Publicado: (2019)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
por: Patel, Sheel A, et al.
Publicado: (2017)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
por: Delanoy, Nicolas, et al.
Publicado: (2021)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines
por: Machioka, Kazuaki, et al.
Publicado: (2018)

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
por: Yamamoto, Teppei, et al.
Publicado: (2020)

Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer
por: Mout, Lisanne, et al.
Publicado: (2021)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Critical appraisal of trastuzumab in treatment of advanced stomach cancer
por: Meza-Junco, Judith, et al.
Publicado: (2011)

Critical appraisal of the Spanner™ prostatic stent in the treatment of prostatic obstruction
por: McKenzie, Patrick, et al.
Publicado: (2011)

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
por: Ferron, Géraldine M., et al.
Publicado: (2013)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
por: Colbourn, Donald
Publicado: (2012)

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
por: Mofid, Bahram, et al.
Publicado: (2015)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
por: Natsagdorj, Ariunbold, et al.
Publicado: (2018)

Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain
por: Gdowski, Andrew S, et al.
Publicado: (2017)

Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer
por: Wan, Zhong, et al.
Publicado: (2020)

The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
por: Sennoune, Souad R., et al.
Publicado: (2020)

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
por: Abidi, Afroz
Publicado: (2013)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
por: Noronha, Vanita, et al.
Publicado: (2016)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Critical appraisal of the potential use of cannabinoids in cancer management
por: Cridge, Belinda J, et al.
Publicado: (2013)

Critical appraisal of lurasidone in the management of schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2012)

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
por: Bahl, A., et al.
Publicado: (2013)

An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer
por: Thiery-Vuillemin, A., et al.
Publicado: (2021)

Intraductal carcinoma of the prostate: a critical re-appraisal
por: Varma, Murali, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kfr4d09cmk22rcv1cll98e8g2r